Full replicate designed study for Europe [RSABE / ABEL]

posted by ElMaestro  – Denmark, 2018-04-02 04:19 (2272 d 20:32 ago) – Posting: # 18627
Views: 2,937


both the fixed effects model (EMA) and the mixed effects model (FDA) are stone cold. You can fit whatever you like and you can get a qualified likelihood-based answer.
EMA's sentence about at least one T and R for each subjects should be interpreted exactly as such (but behind the scenes, this does not imply that every subject contributes with a (one) data point which is fed into a grandiose pot of T/R ratios).

❝ Follow up question for the pros: if you include partially completed subjects, does this unbalancing have an effect on the mixed model?

"have an effect" is a bit vague. The only thing that gets funky is the calculation of denominator df's. In case of data gaps this is not so straightforward and that is one of the topics that cause statisticians to attack each other with some very pugnacious remarks.

Pass or fail!

Complete thread:

UA Flag
 Admin contact
23,059 posts in 4,841 threads, 1,663 registered users;
33 visitors (0 registered, 33 guests [including 8 identified bots]).
Forum time: 00:51 CEST (Europe/Vienna)

[…] an inappropriate study design is incapable of answering
a research question, no matter how careful the subsequent
methodology, conduct, analysis, and interpretation:
Flawless execution of a flawed design achieves nothing worthwhile.    J. Rick Turner

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz